Chronic myeloid leukaemia (CML) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051108
Expand allThis document outlines details of PBS-subsidised imatinib, dasatinib, nilotinib, ponatinib and asciminib for patients with chronic myeloid leukaemia (CML).
CML and listing dates
CML is a type of blood cancer.
Listing dates:
- imatinib - 1 December 2001
- dasatinib - 1 August 2007
- nilotinib - 1 August 2008
- ponatinib - 1 November 2015
- asciminib - 1 May 2023
See Written Authority Required Drugs for more details.
Enquiries
Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs and choose the option relevant to the condition treated.
The Resources page contains:
- application forms
- contact details
- FAQs from service officers
- restriction and item codes
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities system (OPA system)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing and National Demand Allocation (PaNDA)
Processing Complex Authority Required Listings
Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)
Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)